Senescent cells: the hidden link between obesity and metabolic disease

Senescent cell accumulation in visceral adipose tissue acts as a silent engine of metabolic dysfunction, feeding a pathogenic cycle where obesity induces senescence and senescent cells, in turn, amplify systemic inflammation. In overweight individuals, these cells release a complex secretory profile—cytokines, chemokines, and matrix-remodeling enzymes—that perpetuates local metaflammation, impairs insulin signaling, and promotes lipotoxicity across liver, pancreas, and skeletal muscle. What distinguishes accelerated metabolic aging is that while young, lean individuals efficiently clear senescent cells via immune mechanisms, aging and excess weight cause this clearance to falter, enabling progression from hepatic steatosis through MASH (metabolic dysfunction-associated steatohepatitis), fibrosis, and cirrhosis. Rodent models show that reducing senescent cell marker burden improves metabolic parameters, insulin sensitivity, and fibrosis; though human translation remains pending, this opens a radical prospect for biohackers and longevity clinics: senolytic interventions could intercept the inflammatory cycle before chronic cardiometabolic disease consolidates.